Hes1 suppresses acute myeloid leukemia development through FLT3 repression

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Notch signaling plays a context-dependent role in leukemogenesis.
• Hairy and enhancer of split-1 (Hes1) is a key downstream target of Notch signaling, acting as a transcriptional repressor.
• The role of Hes1 in acute myeloid leukemia (AML) development is not fully understood.

Purpose of the Study:

• To investigate the role of Hes1 in MLL-AF9-induced AML development.
• To elucidate the molecular mechanisms by which Hes1 influences AML pathogenesis.
• To determine if Hes1 mediates tumor suppressive functions of Notch signaling in AML.

Main Methods:

• Gene deletion studies in mice (Hes1-null).
• Analysis of FMS-like tyrosine kinase 3 (FLT3) gene promoter activity and expression.
• Cell proliferation assays and Western blotting for ERK phosphorylation.
• Apoptosis induction studies using anti-Notch2 antibodies.
• Correlation analysis of HES1 and FLT3 mRNA expression in patient AML samples.

Main Results:

• Deletion of Hes1 in mice promoted MLL-AF9-induced AML development.
• Hes1 directly repressed FLT3 promoter activity, leading to FLT3 upregulation in Hes1-null cells.
• MLL-AF9-expressing Hes1-null AML cells exhibited enhanced proliferation and ERK phosphorylation upon FLT3 ligand stimulation.
• FLT3 inhibition abrogated proliferation of MLL-AF9-induced Hes1-null AML.
• Notch2 activation induced apoptosis in Hes1-wild type but not Hes1-null AML cells.
• FLT3 mRNA expression was negatively correlated with HES1 mRNA expression in patient AML samples.

Conclusions:

• Hes1 plays a critical tumor-suppressive role in MLL-AF9-induced AML.
• Hes1 likely exerts its tumor suppressive effects by downregulating FLT3 expression.
• These findings highlight Hes1 as a potential therapeutic target in AML, mediated through Notch signaling pathways.